Zioptan (tafluprost ophthalmic solution)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved February 2012

Specific Treatments:

elevated intraocular pressure

Therapeutic Areas

General Information

Zioptan (tafluprost ophthalmic solution) is a fluorinated analog of prostaglandin F2a. It acts on the same receptors in the eye as the natural prostaglandins. It causes an increase in the drainage of aqueous humour out of the eyeball, which decreases the pressure within the eye.

Zioptan was specifically approved for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Zioptan is supplied as a solution for intraocular injection. The recommended initial dose is one drop in the conjunctival sac of the affected eye(s) once daily in the evening.

Clinical Results

FDA Approval
The FDA approval of Zioptan was based on clinical studies up to 24 months in duration. Subjects with open-angle glaucoma or ocular hypertension and baseline pressure of 23 - 26 mm Hg were treated with Zioptan dosed once daily in the evening. Zioptan demonstrated reductions in intraocular pressure at 3 and 6 months of 6 to 8 mmHg and 5 to 8 mmHg, respectively.

Side Effects

Adverse events associated with the use of Zioptan may include, but are not limited to, the following:

  • conjunctival hyperemia
  • ocular stinging/irritation
  • ocular pruritus including allergic conjunctivitis
  • cataract
  • dry eye
  • ocular pain
  • eyelash darkening
  • growth of eyelashes
  • vision blurred

Mechanism of Action

Zioptan (tafluprost ophthalmic solution) is a fluorinated analog of prostaglandin F2a. It is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

Literature References

Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, Noble L, Lines C, Ho TW Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension. American Journal of Ophthalmology 2012 Feb 4

Erb C, Lanzl I, Seidova SF, Kimmich F Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Advances in Therapy 2011 Jul;28(7):575-85

Pozarowska D Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clinical Ophthalmology 2010 Oct 21;4:1229-36

Additional Information

For additional information regarding Zioptan or elevated intraocular pressure, please visit the Zioptan web page.





Bipolar World   1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010
Owners:  Allie Bloom, David Schafer, M.Ed. (Blackdog)

Partners:  John Haeckel, Judith (Duff)
Founder:  Colleen Sullivan
Email Us at Bipolar World

About Us  Add a Link  Advance Directives  Alternative Treatments  Ask the Doctor   Ask Dr. Plyler about Bipolar Disorder   Ask The Doctor/Topic Archives  Awards  Benny the Bipolar Puppy  Bipolar Chat  Bipolar Children  Bipolar Disorder News  Bipolar Help Contract  Bipolar World Forums  Book Reviews  Bookstore  BP & Other mental Illness   Clinical Research Trials & FDA Drug Approval   Community Support   Contact Us  The Continuum of Mania and Depression   Coping   Criteria    Criteria and Diagnosis  Criteria-World Health Disabilities,  DSMV-IV   Dual Diagnosis  eGroups  Expressions (Poetry, Inspiration, Humor, Art Gallery, Memorials  Family Members   Getting Help for a Loved One who Refuses Treatment  Greeting Cards  History of Mental Illness  Indigo  Job and School  Links    Medications   Medication and Weight Gain    News of the Day  Parent Chat  Pay for Meds  Personal Stories  Self Help  Self Injury  Significant Others  Stigma and Mental Health Law  Storm's Column  Suicide!!!  The Suicide Wall  Table of Contents  Treatments  Treatment Compliance  US Disability  Veteran's Chat  What's New?